Fig. 6

In vivo drug response to fulvestrant, BYL719 alone, and combined in 3 ERα-negative models. a Effect of the different treatments on HBCx27 tumor growth. Each treatment included 10 mice; the y-axis indicates the mean of RTV + SD. b PLA was performed and analyzed as in Fig. 2. c IHC staining was performed on formalin-fixed paraffin-embedded PDX tumors using anti-P-S6 riboprotein (S235/6) antibody. d Effect of the different treatments on HBCx-801 tumor growth. Each treatment included 10 mice; the y-axis indicates the mean of RTV + SD. e PLA was performed and analyzed as in Fig. 2. f IHC staining was performed on formalin-fixed paraffin-embedded PDX tumors using anti-P-AKT (S473) and anti-P-S6 riboprotein (S235/6) antibodies. g Effect of the different treatments on HBCx-90 tumor growth. Each treatment included 10 mice; the y-axis indicates the mean of RTV + SD. h PLA was performed and analyzed as in Fig. 2. i IHC staining was performed on fixed PDX tumors using anti-P-AKT (S473) and anti-P-S6 riboprotein (S235/6) antibodies. Quantification of highly, medium, and negative cells was performed as described in the “Materials and methods” section. Significance (P value) between treatments and controls were performed using the t test. ns: not significant